Nitric oxide inhibition rapidly increases blood pressure with no change in outcome in cardiogenic shock: the TRIUMPH trial.

There was, however, a 6% absolute increase in 30-day mortality in the tilarginine group (48%, versus 42% in the placebo) that was qualified by Ndrepepa and colleagues in their editorial in the same issue of JAMA as a disturbing event if this difference did not reach statistical significance ( p = 0.24) [ 9 ].

also in 111,027 other papers